Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 36, 2001 - Issue 11
Submit an article Journal homepage
32
Views
24
CrossRef citations to date
0
Altmetric
Research Article

Sequential Changes in Luminal Microflora and Mucosal Cytokine Expression during Developing of Colitis in HLA-B27/β 2 -Microglobulin Transgenic Rats

K. Hata, A. Andoh, H. Sato, Y. Araki, M. Tanaka, T. Tsujikawa, Y. Fujiyama, T. Bamba
Pages 1185-1192 | Published online: 08 Jul 2009

  • Arseneau KO, Pazarro TT, Cominelli F. Discovering the cause of inflammatory bowel disease: lessons from animal model. Curr Opin Gastroenterol 2000;16:310-7.
  • Bison CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344-67.
  • Inman RD, Scofield RH. Etiopathogenesi of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 1994;6:360-70.
  • Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human ßm: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
  • Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Femandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
  • Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammtory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993;150:4168-78.
  • Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, BalishE, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human/ß2 microglobulin transgenic rats. J Clin Invest 1996; 98:945-53.
  • Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67:2969-74.
  • Rath HC, Ikeda JS, Linde HJ, Schölmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999;116:310-9.
  • Strober W, Fuss IJ, Ehrhaidt RO, Neurath M, Boirivant M, Ludviksson BR. Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol 1998;48:453-8.
  • Strober W, Fuss IJ. Experimental models of inflammation and their relation to human inflammatory bowel disease. In: Domschke W, Stall R, Brasitus TA, Kagnoff MF, editors. FaIk Symposium 110. Intestinal mucosa and its diseases. Pathophysiology and Clinics. Dordrecht: Kluwer Academic Publishers; 1999. p. 457-70.
  • Kucharzik T, Lügering N, Stoll R, Domschke W. Regulation of inflammatory response by suppressor cytokines. In: Domschke W, Stoll R, Brasitus TA, Kagnoff MF, editors. FaIk Symposium 110. Intestinal mucosa and its diseases. Pathophysiology and Clinics. Dordrecht: Kluwer Academic Publishers; 1999. p. 471-82.
  • Levine AD, Fiocchi C. Cytokines: opportunities for therapeutic intervention. In: Gaginella TS, Guglietta A, editors. Drug development: molecular targets for gastrointestinal diseases. Totowa: Human Press; 1999. p. 61-87.
  • Panonchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
  • Puss II, Neurath M, Boirivant M, Klein IS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.1 Immunol 1996;157:1261 -70.
  • Sartor RB. Cytokine in intestinal inflammation: pathophysiological and clinical consideration. Gastroenterology 1994;106: 533-9.
  • Davidson NI, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-y, plays a major role in sustaining the chronic phase of colitis in IL-10-deflcient mice. J Immunol 1998;161:3143-9.
  • Mizoguchi A, Mizoguchi E, Bhan AK. The critical role of interleukin-4 but not interferon-y in the pathogènesis of colitis in T cell receptor a mutant mice. Gastroenterology 1999;116: 320-6.
  • Bertrand V, Quere S, Guimbaud R, Sogni P, Chauvelot-Moachon L, Tulliez M, et al. Effects of murine recombinant interleukin-1 O on the inflammatory disease of rats transgenic for HLA-B27 and human fa microglobulin. Eur Cytokine Netw 1998;9:161-70.
  • Holdeman LV, Kelley RW, Moore EC. Anaerobic gramnegative straight, curved and helical rods. In: Krieg NR, Holt IG, editors. Bergey's manual of systematic bacteriology. Vol. 1. Baltimore: Williams & Wilkins; 1984. p. 602-30.
  • McKnight AI, Barclay AN, Mason DW. Molecular cloning of rat interleukin-4 CDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells. Eur I Immunol 1991;21:1187-94.
  • Goodman RE, Oblak J, Bell RG. Synthesis and characterization of rat interleukin-10 (IL-IO) cDNA clones from the RNA of cultured OX8- OX22- thoracic duct T cells. Biochem Biophys Res Commun 1992;189:l-7.
  • Mathieson PW, Gillespie KM. Cloning of a partial cDNA for rat interleukin-1 2 (IL-12) and analysis of IL-12 expression in vivo. Scand J Immunol 1996;44:11-4.
  • Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor ß1. Nucleic Acids Res 1990;18:3059.
  • Katz IA, Itoh J, Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 1999;15:291-7.
  • Krook A, Lindstrom B, Kjellander I, Iamerot G, Bodin L. Relation between concentrations of metronidazole and Bacteroides spp. in faeces of patients with Crohn's disease and healthy individuals. I Clin Pathol 1981:34:645-50.
  • Sutherland L, Singleton I, Sessions I, Hanauer S, Krawitt E, Rankin G, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991:32:1071-5.
  • Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon TJ. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997;39:393-400.
  • Auer IO, Roder A, Wensinck F, van de Merwe JP, Schmidt H. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1983;18:217-23.
  • Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000;15:61-8.
  • Fujiyama Y, Kobayashi K, Senda S, Benno Y, Bamba T, Hosoda S. A novel IgA piotease from Clostridium sp. Capable of cleaving IgAl and IgA2 A2m(l) but not IgA2 A2m(2) allotype paraproteins. J Immunol 1985;134:573-6.
  • Madsen KL, Doyle JS, Tavernini MN, Jewell LD, Pennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin-10 gene-deficient mice. Gastroenterology 2000;118:1094-105.
  • Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994:84:4008-27.
  • Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin-1 2 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
  • Lugering N, Kucharzik T, Stein H, Winde G, Lugering A, Hasilik A, et al. IL-IO synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sci 1998;43:706-14.
  • Kucharzik T, Lugering N, Adolf M, Domschke W, Stoll R. Synergisti c effect of immunoregulatory cytokine s on peripheral blood monocytes from patients with inflammatory bowel disease. Dig Dis Sei 1997:42:805-12.
  • Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcy receptor type I. J Exp Med 1998;188:217-22.
  • Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonie mucosa. J Exp Med 1998:187:389- 402.
  • Holmgren J, Czerkinsky C, Lebens M, Rudin A, Sun JB, Svennerholm AM. Mucosal vaccines and oral torelance. In: Domschke W, Stoll R, Brasitus TA, Kagnoff MF, editors. FaIk Symposium 110. Intestinal mucosa and its diseases. Pathophysiology and Clinics. Dordrecht: Kluwer Academic Publishers; 1999. p. 361-72.
  • Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, et al. Hapten-induced model of murine inflammatory bowel disease: mucosal immune responses and protection by tolerance. J Immunol. 1996;157:2174-85.
  • Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996:183:2605-16.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.